Bayer's mRNA Patent Win, Rare-Drug Nods and a EUR 2 Billion Bond Sale Collide With a 10% Weekly Slide

Delaware court lets Bayer's mRNA patent case against Pfizer, BioNTech and Moderna proceed; Lynkuet gets FDA priority review and BlueRock candidate wins orphan status.

A Delaware federal court handed Bayer's Monsanto unit a procedural victory on September 28, turning back motions from Pfizer, BioNTech and Moderna that sought dismissal of patent claims filed against them over messenger-RNA technology. Reuters reported that Bayer welcomed the ruling and considers its legal footing reinforced. With the judge's decision clearing the way, the case can now proceed to the merits — a matter of real financial consequence for the Leverkusen-based agriculture and pharmaceutical group, since the dispute centers on rights to foundational mRNA processes that underpinned billions in vaccine revenue in recent years.

The courtroom development was not the only item on Bayer's late-September agenda. On the same day, the US Food and Drug Administration granted priority review status to Lynkuet (elinzanetant) for an additional indication: treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer.

BlueRock Candidate Secures Orphan Designation on Both Sides of the Atlantic

Bayer's cell-therapy subsidiary BlueRock Therapeutics LP reported parallel progress, with both the FDA and the European Medicines Agency awarding orphan-drug status to the development candidate lemiretprocel (OpCT-001). The designation targets inherited retinal conditions including retinitis pigmentosa and cone-rod dystrophy, and comes with procedural support for the clinical trials ahead.

Behind the pipeline news, Bayer is also reshaping leadership in its prescription-medicines business. On Thursday the company named Dr. Christoph Koenen as Chief Medical Officer of the pharma division, effective October 1. Koenen will hold the role alongside his existing duties heading clinical development and operations — a consolidation that puts strategic development programs under a single hand.

Stivarga Sale and a Fresh EUR 2 Billion in Hybrid Debt

Portfolio housekeeping has been running in parallel. On September 21, Bayer agreed to sell rights to the cancer drug Stivarga to pharmaceutical company Grünenthal for up to EUR 375 million, with completion expected in late 2026 or early 2027.

Financing followed two days later. On September 23, the group placed hybrid bonds totaling EUR 2 billion, split into two EUR 1 billion tranches carrying coupons of 5.75% and 6.25%, each with first call rights after six and nine years respectively. The issuance lifted Bayer's total outstanding volume of these subordinated notes to EUR 6.55 billion.

Shares Retreat 10% Over Seven Days Despite Year-to-Date Gains

Equity markets have taken a more cautious view. The stock closed Friday's session at EUR 45.02, a 10% decline over seven trading days, with media reports pointing to the unresolved US glyphosate litigation as the main drag on sentiment. Even so, the shares remain up 22% since the start of the year.